Mendelian randomization estimates were consistent with an effect of Cer22:0 on T2D risk, and gene set enrichment analyses suggestively linked Cer18:0 to insulin signaling and both ceramides to cytokine-induced inflammation. This evidence concerns the gene INS and type 2 diabetes mellitus.